PAR-1 antagonist vorapaxar favorably improves global thrombotic status in patients with coronary disease. Rosser G, Tricoci P, Morrow D, Christopoulos C, Niespialowska-Steuden MN, Kozarski R, Wilcox R, Gorog DA. J Thromb Thrombolysis. 2014 Nov;38(4):423-9. doi: 10.1007/s11239-014-1075-4. PMID: 24676931 Clinical Trial.

Activity: Other activity typesOther

Period2014